Aetna Tackles Quality Issues In Genetic Testing For Breast Cancer - Promoting Evidence-based Approach
Aetna (NYSE:AET) is implementing a comprehensive plan to increase the quality of genetic diagnosis and treatment of breast cancer. The company is guiding members and physicians to laboratories that meet national guidelines for genetic testing accuracy. Aetna also is funding research to understand the use of genetic tests in breast cancer treatment.
More: continued here
Filed under: Breast Cancer on November 2nd, 2008